DSP Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

DSP Healthcare Growth Direct Plan

NAV
₹35.2440
-0.88%
(12 Apr)
AUM
2,352 Cr
TER
0.64%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+103.2%
+101.2%
+84.7%
+69.1%
+55.9%
3Y
+46.2%
+43.3%
+42.6%
+41.8%
+19.1%
5Y
NA
+25.0%
+37.5%
+28.0%
+27.8%
ALL
+34.7%
+12.9%
+20.9%
+18.3%
+26.7%
VOL
21.8%
19.9%
20.2%
18.1%
14.9%
TER
0.5%
1.0%
0.7%
1.0%
0.6%
AUM
₹3,404 Cr
₹1,876 Cr
₹2,498 Cr
₹5,186 Cr
₹2,352 Cr
INFO
1.59
0.65
1.03
1.01
1.80
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
DSP Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 29th Feb
Top holdings
Sun Pharmaceuticals Industries Ltd
13.9%
Cipla Ltd
8.2%
Ipca Laboratories Ltd
8.0%
Lupin Ltd
7.6%
Suven Pharmaceuticals Ltd
7.6%
Alembic Pharmaceuticals Ltd
5.9%
Apollo Hospitals Enterprise Ltd
4.9%
Globus Medical Inc Class A
4.3%
Concord Biotech Ltd
3.9%
Procter & Gamble Health Ltd
3.5%
Top industry exposure
Healthcare
95.2%
Financial Services
1.8%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
14%
Lock-in period
-
Exit load
• 0.5% for redemption within 30 days
Fund objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Fund manager(s)
Jay Kothari
Chirag Dagli

FAQs